Skip to main content

Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.

Publication ,  Journal Article
Roberts, MC; Weinberger, M; Dusetzina, SB; Dinan, MA; Reeder-Hayes, KE; Carey, LA; Troester, MA; Wheeler, SB
Published in: J Clin Oncol
January 10, 2016

PURPOSE: Oncotype DX (ODX) is a tumor gene-profiling test that aids in adjuvant chemotherapy decision-making. ODX has the potential to improve quality of care; however, if not equally accessible across racial groups, disparities in cancer care quality may persist or worsen. We examined racial disparities in ODX testing uptake. METHODS: We used data from the Carolina Breast Cancer Study, phase III, a longitudinal, population-based study of 2,998 North Carolina women who received a diagnosis of breast cancer between 2008 and 2014. Our primary analysis used modified Poisson regression to determine the association between race and whether ODX testing was ordered among two strata: node-negative and node-positive breast cancer. RESULTS: A total of 1,468 women with estrogen receptor-positive, human epidermal growth factor receptor-2-negative, stage I or II breast cancer met inclusion criteria. Black patients had higher-grade and larger tumors, more comorbidities, younger age at diagnosis, and lower socioeconomic status than non-black women. Overall, 42% of women had ODX test results in their pathology reports. Compared with those who did not receive ODX testing, women who received ODX testing tended to be younger and have medium tumor size and grade. Our regression analyses indicated no racial disparities in ODX uptake among node-negative patients. However, racial differences were detected among node-positive patients, with black patients being 46% less likely to receive ODX testing than non-black women (adjusted relative risk, 0.54; 95% CI, 0.35 to 0.84; P = .006). CONCLUSION: We did not find racial disparities in ODX testing for node-negative patients for whom ODX testing is guideline recommended and widely covered by insurers. However, our findings suggest that a newer, non-guideline-concordant application of ODX testing for node-positive breast cancer was accessed less by black women than by non-black women, reflecting more guideline concordant care among black women.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

January 10, 2016

Volume

34

Issue

2

Start / End Page

130 / 138

Location

United States

Related Subject Headings

  • Risk Factors
  • Risk Assessment
  • Research Design
  • Predictive Value of Tests
  • Precision Medicine
  • Practice Guidelines as Topic
  • Poisson Distribution
  • Oncology & Carcinogenesis
  • North Carolina
  • Neoplasm Staging
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Roberts, M. C., Weinberger, M., Dusetzina, S. B., Dinan, M. A., Reeder-Hayes, K. E., Carey, L. A., … Wheeler, S. B. (2016). Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer. J Clin Oncol, 34(2), 130–138. https://doi.org/10.1200/JCO.2015.63.2489
Roberts, Megan C., Morris Weinberger, Stacie B. Dusetzina, Michaela A. Dinan, Katherine E. Reeder-Hayes, Lisa A. Carey, Melissa A. Troester, and Stephanie B. Wheeler. “Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.J Clin Oncol 34, no. 2 (January 10, 2016): 130–38. https://doi.org/10.1200/JCO.2015.63.2489.
Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Carey LA, et al. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer. J Clin Oncol. 2016 Jan 10;34(2):130–8.
Roberts, Megan C., et al. “Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.J Clin Oncol, vol. 34, no. 2, Jan. 2016, pp. 130–38. Pubmed, doi:10.1200/JCO.2015.63.2489.
Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Carey LA, Troester MA, Wheeler SB. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer. J Clin Oncol. 2016 Jan 10;34(2):130–138.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

January 10, 2016

Volume

34

Issue

2

Start / End Page

130 / 138

Location

United States

Related Subject Headings

  • Risk Factors
  • Risk Assessment
  • Research Design
  • Predictive Value of Tests
  • Precision Medicine
  • Practice Guidelines as Topic
  • Poisson Distribution
  • Oncology & Carcinogenesis
  • North Carolina
  • Neoplasm Staging